Physician profile
Michael L Sinitsa
NPI 1922009307
$3,159.61
in general payments reported to CMS, 2019-2025
27 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $449 · 2021: $214 · 2022: $456 · 2023: $392 · 2024: $310 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $595.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.53 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $314.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $304.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $234.40 | 2019-2025 | Shingrix |
| Lilly USA, LLC | $201.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $165.62 | 2022-2025 | Vraylar, Qulipta |
| Merck Sharp & Dohme LLC | $160.45 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Amgen INC. | $135.87 | 2019-2022 | |
| Amarin Pharma, INC. | $131.35 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $82.48 | 2019-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $72.35 | 2022-2025 | |
| Astellas Pharma US INC | $53.20 | 2023-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $52.81 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $51.01 | 2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $36.91 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $29.45 | 2021 | |
| Allergan, INC. | $22.22 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.46 | 2019 | |
| Shire North American Group INC | $20.76 | 2019 | |
| Sanofi Pasteur INC. | $19.97 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.74 | 2025 | Voquezna |
| Biogen, INC. | $18.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.43 | 2020 | |
| Abbott Laboratories | $14.96 | 2024 | Freestyle Libre 3 |
| Grt US Holding, INC. | $12.81 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sinitsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.